Sale of Speciality Coal Inventory to Hargreaves Raw Material Services GmbH ( HRMS ) Hargreaves Services plc (AIM: HSP), a diversified group delivering services to the industrial and property sectors, is pleased to announce the sale of its entire inventory of speciality coal to its German Joint Venture, HRMS, ending its material direct business interests in coal. Hargreaves has sold all of the speciality coal held at its two UK stockholding sites to HRMS for a cash consideration of approximately £24m. Hargreaves remaining coal stocks comprise heavy industrial coal, which is expected to be sold to third parties over the remainder of the current financial year. The Group expects to have no material coal inventory by 31 May 2021, the end of the current financial year.
IMPORTANT NOTICES Neither this Announcement (including the information contained in them), nor any copy of it, may be taken or transmitted, published or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, New Zealand or the Republic of South Africa or to any persons in any of those jurisdictions or any other jurisdiction where to do so would constitute a violation of the relevant securities laws of such jurisdiction. This Announcement is for information purposes only and does not constitute an offer to sell or issue, or the solicitation of an offer to buy, acquire or subscribe for any shares in the capital of the Company in the United States, Australia, Canada, Japan, New Zealand or the Republic of South Africa or any other state or jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Any failure to comply with these restrictions may constitute a v
Merger of Davies Odell with Vale Brothers
The Board of CEPS is pleased to announce that its subsidiary company, Davies Odell Limited ( Davies Odell ), has undertaken a merger with Vale Brothers Limited ( Vale Brothers ). This merger has been achieved by the incorporation of a new company, Vale Brothers Holdings Limited ( VBH ), which has acquired 100% of the share capital of both Davies Odell and Vale Brothers.
Davies Odell has of late been loss-making and despite much effort and investment has been unable, to date, to move into sustained profitability.
Vale Brothers is larger in terms of turnover than Davies Odell (for the year ending 31 December 2019 turnover was £4.6m and £3.6m respectively) and manufactures and supplies a range of branded products for the equestrian market. In this respect there is an interesting overlap with Davies Odell which has a complementary range of products addressing the same markets.
Imperial X Plc - Participation in Private Placement
PR Newswire
Participation in Private Placement
Imperial X Plc is pleased to announce that is has participated in a private placement undertaken by Imperial Helium Corp. ( Imperial Helium ) a Canadian company which is focused on acquiring and developing helium resources in the western Canadian Sedimentary Basin.
Subject to completion of the proposed acquisitions announced on 28 August 2020, Imperial X will own 450,000 preference shares in Imperial Helium through the acquisition of Cloudbreak Discovery Corp.
Imperial Helium is undertaking a private placement in advance of its proposed admission to a public equity market during the first quarter of 2021. The private placement has to date raised C$493,000 out of a target raise of C$1,000,000 through the issue of convertible debentures with a 10% coupon, maturing 18 months from the date of issuance, converting automatically into common shares of Imperial Helium at the IPO at a 20% d
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca®
Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 … Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024